4SC licenses Kv1.3 inhibitors to Maruho
Maruho to receive exclusive worldwide license on 4SC's preclinical inhibitors of the Kv1.3 ion channel 4SC eligible for…
Maruho to receive exclusive worldwide license on 4SC's preclinical inhibitors of the Kv1.3 ion channel 4SC eligible for…
Immunic AG (Immunic), a recently formed private start-up biotech company in Planegg-Martinsried near Munich, Germany, to…
4SC AG (4SC, FSE Prime Standard: VSC) has entered into a licensing and development partnership for the cancer compound 4…
4SC AG (4SC, FWB Prime Standard: VSC) has received an "investigational new drug" (IND) approval from the US Food and Dru…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs mainly foc…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer…
Safety, tolerability and efficacy of resminostat in combination with S-1 chemotherapy will be investigated in various do…
4SC AG (Frankfurt, Prime Standard: ISIN DE000A14KL72, VSC), a discovery and development company of targeted small molecu…
4SC AG (Frankfurt, Prime Standard: ISIN DE000A14KL72, VSC), a discovery and development company of targeted small molecu…
4SC AG (Frankfurt, Prime Standard: VSC) today decided to hold an Extraordinary General Meeting on 11 March 2015. The pri…